Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)-Cancer Endpoints

CompletedOBSERVATIONAL

Enrollment

105,711

Participants

Timeline

Start Date

March 10, 2021

Primary Completion Date

December 31, 2021

Study Completion Date

May 16, 2022

Conditions

Rheumatoid Arthritis

Interventions

DRUG

Tofacitinib

First eligible prescription for treating rheumatoid arthritis (RA)

DRUG

TNF Inhibitor

First eligible prescription for treating rheumatoid arthritis (RA)

Trial Locations (1)

Brigham And Women's Hospital, Boston

All Listed Sponsors

lead

Brigham and Women's Hospital

OTHER

NCT04798287 - Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)-Cancer Endpoints | Biotech Hunter | Biotech Hunter